Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

An immune cell spray (ICS) formulation allows for the delivery of functional monocyte/macrophages.

Beneke V, Küster F, Neehus AL, Hesse C, Lopez-Rodriguez E, Haake K, Rafiei Hashtchin A, Schott JW, Walter D, Braun A, Wolkers WF, Ackermann M, Lachmann N.

Sci Rep. 2018 Nov 2;8(1):16281. doi: 10.1038/s41598-018-34524-2.

2.

Uncoupling the Oncogenic Engine.

Schambach A, Schott JW, Morgan MA.

Cancer Res. 2017 Nov 15;77(22):6060-6064. doi: 10.1158/0008-5472.CAN-17-2362. Epub 2017 Nov 2. Review.

3.

Correction to: Potent and reversible lentiviral vector restriction in murine induced pluripotent stem cells.

Geis FK, Galla M, Hoffmann D, Kuehle J, Zychlinski D, Maetzig T, Schott JW, Schwarzer A, Goffinet C, Goff SP, Schambach A.

Retrovirology. 2017 Oct 18;14(1):48. doi: 10.1186/s12977-017-0372-3.

4.

Integrating Vectors for Gene Therapy and Clonal Tracking of Engineered Hematopoiesis.

Biasco L, Rothe M, Schott JW, Schambach A.

Hematol Oncol Clin North Am. 2017 Oct;31(5):737-752. doi: 10.1016/j.hoc.2017.06.009. Review.

PMID:
28895844
5.

Potent and reversible lentiviral vector restriction in murine induced pluripotent stem cells.

Geis FK, Galla M, Hoffmann D, Kuehle J, Zychlinski D, Maetzig T, Schott JW, Schwarzer A, Goffinet C, Goff SP, Schambach A.

Retrovirology. 2017 May 31;14(1):34. doi: 10.1186/s12977-017-0358-1.

6.

Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells.

Hoffmann D, Schott JW, Geis FK, Lange L, Müller FJ, Lenz D, Zychlinski D, Steinemann D, Morgan M, Moritz T, Schambach A.

Gene Ther. 2017 May;24(5):298-307. doi: 10.1038/gt.2017.20. Epub 2017 Apr 20.

PMID:
28346436
7.

Viral and Synthetic RNA Vector Technologies and Applications.

Schott JW, Morgan M, Galla M, Schambach A.

Mol Ther. 2016 Sep;24(9):1513-27. doi: 10.1038/mt.2016.143. Epub 2016 Jul 5. Review.

8.

Retrovirus-based vectors for transient and permanent cell modification.

Schott JW, Hoffmann D, Schambach A.

Curr Opin Pharmacol. 2015 Oct;24:135-46. doi: 10.1016/j.coph.2015.09.004. Epub 2015 Oct 1. Review.

PMID:
26433198
9.

Deciphering the impact of parameters influencing transgene expression kinetics after repeated cell transduction with integration-deficient retroviral vectors.

Schott JW, Jaeschke NM, Hoffmann D, Maetzig T, Ballmaier M, Godinho T, Cathomen T, Schambach A.

Cytometry A. 2015 May;87(5):405-18. doi: 10.1002/cyto.a.22650. Epub 2015 Feb 27.

10.

Improved retroviral episome transfer of transcription factors enables sustained cell fate modification.

Schott JW, Hoffmann D, Maetzig T, Müller FJ, Steinemann D, Zychlinski D, Cantz T, Baum C, Schambach A.

Gene Ther. 2014 Nov;21(11):938-49. doi: 10.1038/gt.2014.69. Epub 2014 Aug 7.

PMID:
25102011
11.

Viral and non-viral approaches for transient delivery of mRNA and proteins.

Schott JW, Galla M, Godinho T, Baum C, Schambach A.

Curr Gene Ther. 2011 Oct;11(5):382-98. Review.

PMID:
21787295

Supplemental Content

Loading ...
Support Center